Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 13:4:100166.
doi: 10.1016/j.cccb.2023.100166. eCollection 2023.

Effects of multidomain lifestyle interventions on cognitive decline and Alzheimer's disease prevention: A literature review and future recommendations

Sasja Noach  1 , Ben Witteman  1   2 , H Myrthe Boss  3 , André Janse  2
Affiliations
Review

Effects of multidomain lifestyle interventions on cognitive decline and Alzheimer's disease prevention: A literature review and future recommendations

Sasja Noach et al. Cereb Circ Cogn Behav. .

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder with an increasing incidence and currently without a cure. It is speculated that targeting multiple modifiable risk factors (MRFs) could be a beneficial strategy for the prevention of cognitive decline and AD. This study provides an overview and discusses the existing literature on multidomain lifestyle interventions in relation to cognitive decline and the prevention of AD. A literature search was performed in PubMed and Scopus, for studies published in English up to 31 May 2021. We identified nine relevant studies on the effect of multidomain lifestyle interventions on cognition (n = 8) and/or AD incidence or risk scores (n = 4). The studies included a combination of the separate intervention components diet (n = 8), physical activity (n = 9), cognitive activity (n = 6), metabolic or cardiovascular risk factor reduction strategies (n = 8), social activity (n = 2), medication (n = 2), and/or supplementation (n = 1). Global cognition was improved significantly in four of the eight studies that had global cognition as the outcome. Moreover, significant improvements were shown for cognitive domains in two of the three studies with specific cognitive domains as an outcome. No effect on AD incidence was observed, although positive results were shown for AD risk scores. The results suggest that multidomain lifestyle intervention studies may be partially effective in preventing cognitive decline. However, studies were heterogeneous and limited in follow-up. Future research on the effect of multidomain lifestyle interventions on cognitive decline and AD incidence must be conducted with a longer follow-up period.

Keywords: Alzheimer's disease; Cognition; Cognitive decline; Modifiable risk factor; Multidomain lifestyle intervention.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Flow diagram of the identified, screened and included multidomain lifestyle intervention studies on cognitive decline and AD prevention outcome.
See this image and copyright information in PMC

References

    1. Alzheimer's Disease International, 2018. World Alzheimer Report 2018 - The state of the art of dementia research: new frontiers.
    1. Andrieu S., Guyonnet S., Coley N., Cantet C., Bonnefoy M., Bordes S., Bories L., Cufi M.N., Dantoine T., Dartigues J.F., Desclaux F., Gabelle A., Gasnier Y., Pesce A., Sudres K., Touchon J., Robert P., Rouaud O., Legrand P., Payoux P., Caubere J.P., Weiner M., Carrié I., Ousset P.J., Vellas B., Vellas B., Guyonnet S., Carrié I., Brigitte L., Faisant C., Lala F., Delrieu J., Villars H., Combrouze E., Badufle C., Zueras A., Andrieu S., Cantet C., Morin C., Van Kan G.A., Dupuy C., Rolland Y., Caillaud C., Ousset P.J., Fougère B., Willis S., Belleville S., Gilbert B., Fontaine F., Dartigues J.F., Marcet I., Delva F., Foubert A., Cerda S., Noëlle-Cuffi M., Costes C., Rouaud O., Manckoundia P., Quipourt V., Marilier S., Franon E., Bories L., Pader M.L., Basset M.F., Lapoujade B., Faure V., Li M., Tong Y., Malick-Loiseau C., Cazaban-Campistron E., Desclaux F., Blatge C., Dantoine T., Laubarie-Mouret C., Saulnier I., Clément J.P., Picat M.A., Bernard-Bourzeix L., Willebois S., Désormais I., Cardinaud N., Bonnefoy M., Livet P., Rebaudet P., Gédéon C., Burdet C., Terracol F., Pesce A., Roth S., Chaillou S., Louchart S., Sudres K., Lebrun N., Barro-Belaygues N., Touchon J., Bennys K., Gabelle A., Romano A., Touati L., Marelli C., Pays C., Robert P., Le Duff F., Gervais C., Gonfrier S., Gasnier Y., Bordes S., Begorre D., Carpuat C., Khales K., Lefebvre J.F., El Idrissi S.M., Skolil P., Salles J.P., Dufouil C., Lehéricy S., Chupin M., Mangin J.F., Bouhayia A., Allard M., Ricolfi F., Dubois D., Paule M., Martel B., Cotton F., Bonafé A., Chanalet S., Hugon F., Bonneville F., Cognard C., Chollet F., Payoux P., Voisin T., Peiffer S., Hitzel A., Allard M., Zanca M., Monteil J., Darcourt J., Molinier L., Derumeaux H., Costa N., Vincent C., Perret B., Vinel C., Olivier-Abbal P. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377–389. doi: 10.1016/S1474-4422(17)30040-6. - DOI - PubMed
    1. Armstrong R.A. Risk factors for Alzheimer's disease. Folia Neuropathol. 2019;57:87–105. doi: 10.5114/FN.2019.85929. - DOI - PubMed
    1. Bott N.T., Hall A., Madero E.N., Glenn J.M., Fuseya N., Gills J.L., Gray M. Face-to-face and digital multidomain lifestyle interventions to enhance cognitive reserve and reduce risk of alzheimer's disease and related dementias: a review of completed and prospective studies. Nutrients. 2019 doi: 10.3390/nu11092258. - DOI - PMC - PubMed
    1. Burnham S.C., Raghavan N., Wilson W., Baker D., Ropacki M.T., Novak G., Ames D., Ellis K., Martins R.N., Maruff P., Masters C.L., Romano G., Rowe C.C., Savage G., Macaulay S.L., Narayan V.A. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal Alzheimer's disease trials: an AIBL study. J. Alzheimer's Dis. 2015;46:1079–1089. doi: 10.3233/JAD-143015. - DOI - PubMed

LinkOut - more resources